ADC Therapeutics (ADCT) Net Income Growth (3y) (2023 - 2026)

ADC Therapeutics (ADCT) Net Income Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Oculis Holding AG 67,042.03 Bn 67,041.74 Bn - 9.16%
2 Nanobiotix 1,908.00 Bn 1,907.94 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 472.89 Bn 468.10 Bn 1.35 Bn 38.43%
5 Vertex Pharmaceuticals 122.12 Bn 114.87 Bn 2.59 Bn 13.80%
6 Regeneron Pharmaceuticals 70.04 Bn 61.29 Bn 3.31 Bn -3.84%
7 Belite Bio 62.68 Bn 62.68 Bn - -
8 Argenx Se 55.90 Bn 50.72 Bn 1.41 Bn 79.26%
9 Alnylam Pharmaceuticals 37.47 Bn 34.46 Bn 959.66 Mn 47.10%
10 ADC Therapeutics 174.95 Mn -56.06 Mn 17.38 Mn 17.83%

Historic Data

Download Data
DateValue
Mar 31, 2026 17.83%
Sep 30, 2025 6.80%
Jun 30, 2025 4.17%
Mar 31, 2025 -32.32%
Sep 30, 2024 15.15%
Jun 30, 2024 20.88%
Mar 31, 2024 3.71%
Sep 30, 2023 -30.62%
Jun 30, 2023 27.51%
Mar 31, 2023 -10.98%